Market Closed -
Nasdaq
21:30:01 03/05/2024 BST
|
5-day change
|
1st Jan Change
|
17.15
USD
|
-0.58%
|
|
+16.59%
|
+151.47%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,242
|
2,006
|
707.5
|
213.1
|
297.5
|
752.4
|
-
|
-
|
Enterprise Value (EV)
1 |
1,242
|
1,891
|
525.9
|
107.3
|
219.8
|
643.7
|
622.9
|
590.6
|
P/E ratio
|
-13.6
x
|
-16.7
x
|
-12.7
x
|
-2.23
x
|
-13.9
x
|
-33.3
x
|
-39.9
x
|
-16.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
96.7
x
|
20.3
x
|
3.27
x
|
3.51
x
|
7.77
x
|
6.46
x
|
5.89
x
|
EV / Revenue
|
-
|
91.1
x
|
15.1
x
|
1.64
x
|
2.59
x
|
6.64
x
|
5.34
x
|
4.62
x
|
EV / EBITDA
|
-15
x
|
-15.8
x
|
-4.59
x
|
-1.14
x
|
-8.81
x
|
2.23
x
|
1.87
x
|
-318
x
|
EV / FCF
|
-16.5
x
|
-20.7
x
|
-5.09
x
|
-1.41
x
|
-
|
-19.5
x
|
-20.1
x
|
-
|
FCF Yield
|
-6.08%
|
-4.83%
|
-19.6%
|
-70.7%
|
-
|
-5.13%
|
-4.98%
|
-
|
Price to Book
|
6.24
x
|
18.8
x
|
3.89
x
|
1.95
x
|
2.95
x
|
14.2
x
|
11.9
x
|
9.63
x
|
Nbr of stocks (in thousands)
|
39,728
|
40,514
|
43,644
|
43,668
|
43,622
|
43,873
|
-
|
-
|
Reference price
2 |
31.25
|
49.51
|
16.21
|
4.880
|
6.820
|
17.15
|
17.15
|
17.15
|
Announcement Date
|
12/03/20
|
25/02/21
|
24/02/22
|
30/03/23
|
29/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
20.75
|
34.9
|
65.27
|
84.82
|
96.88
|
116.6
|
127.8
|
EBITDA
1 |
-82.84
|
-119.5
|
-114.7
|
-93.97
|
-24.94
|
288.1
|
333
|
-1.855
|
EBIT
1 |
-83
|
-119.9
|
-115.4
|
-94.81
|
-25.67
|
-23.78
|
-20.82
|
-43.05
|
Operating Margin
|
-
|
-578%
|
-330.78%
|
-145.27%
|
-30.27%
|
-24.54%
|
-17.86%
|
-33.69%
|
Earnings before Tax (EBT)
1 |
-81.03
|
-119.3
|
-55.28
|
-95.57
|
-20.87
|
-23.81
|
-33.52
|
-62
|
Net income
1 |
-81.03
|
-119.3
|
-55.28
|
-95.57
|
-21.43
|
-23.1
|
-22.9
|
-62
|
Net margin
|
-
|
-575.12%
|
-158.39%
|
-146.43%
|
-25.26%
|
-23.85%
|
-19.65%
|
-48.52%
|
EPS
2 |
-2.300
|
-2.970
|
-1.280
|
-2.190
|
-0.4900
|
-0.5150
|
-0.4300
|
-1.025
|
Free Cash Flow
1 |
-75.46
|
-91.41
|
-103.2
|
-75.92
|
-
|
-33
|
-31
|
-
|
FCF margin
|
-
|
-440.51%
|
-295.79%
|
-116.32%
|
-
|
-34.06%
|
-26.6%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/03/20
|
25/02/21
|
24/02/22
|
30/03/23
|
29/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
8.965
|
9.598
|
10.49
|
10.8
|
12.54
|
31.45
|
20.25
|
20.75
|
20.45
|
23.36
|
22.22
|
23.96
|
24.97
|
25.8
|
25.1
|
EBITDA
|
-28.56
|
-35.47
|
-27.5
|
-39.76
|
-25.79
|
-0.923
|
-7.319
|
-6.999
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-28.7
|
-35.76
|
-27.7
|
-39.94
|
-26.02
|
-1.153
|
-7.501
|
-7.223
|
-7.749
|
-3.199
|
-6.709
|
-6.163
|
-6.269
|
-6.066
|
-
|
Operating Margin
|
-320.18%
|
-372.56%
|
-264.11%
|
-369.96%
|
-207.52%
|
-3.67%
|
-37.04%
|
-34.81%
|
-37.89%
|
-13.69%
|
-30.19%
|
-25.72%
|
-25.1%
|
-23.51%
|
-
|
Earnings before Tax (EBT)
1 |
-28.86
|
-36.89
|
-28.07
|
-41.13
|
-27.53
|
1.157
|
-6.39
|
-6.123
|
-7.56
|
-0.793
|
-6.095
|
-5.949
|
-6.057
|
-5.714
|
-
|
Net income
1 |
-28.86
|
-36.89
|
-28.07
|
-41.13
|
-27.53
|
1.157
|
-6.39
|
-6.302
|
-7.747
|
-0.988
|
-6.095
|
-5.949
|
-6.057
|
-5.714
|
-
|
Net margin
|
-321.9%
|
-384.38%
|
-267.67%
|
-380.95%
|
-219.56%
|
3.68%
|
-31.55%
|
-30.37%
|
-37.88%
|
-4.23%
|
-27.43%
|
-24.83%
|
-24.26%
|
-22.14%
|
-
|
EPS
2 |
-0.6600
|
-0.8500
|
-0.6400
|
-0.9400
|
-0.6300
|
0.0300
|
-0.1500
|
-0.1400
|
-0.1800
|
-0.0200
|
-0.1525
|
-0.1500
|
-0.1475
|
-0.1350
|
-0.1100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
04/11/21
|
24/02/22
|
09/05/22
|
08/08/22
|
07/11/22
|
30/03/23
|
08/05/23
|
10/08/23
|
13/11/23
|
29/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
115
|
182
|
106
|
77.7
|
109
|
130
|
162
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-75.5
|
-91.4
|
-103
|
-75.9
|
-
|
-33
|
-31
|
-
|
ROE (net income / shareholders' equity)
|
-47.7%
|
-78.3%
|
-38.7%
|
-66.1%
|
-20.4%
|
-18.8%
|
-4.69%
|
1.69%
|
ROA (Net income/ Total Assets)
|
-44%
|
-68.5%
|
-32.1%
|
-54%
|
-
|
-
|
-
|
-
|
Assets
1 |
184.1
|
174.2
|
172.4
|
177.1
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
5.010
|
2.640
|
4.170
|
2.500
|
2.310
|
1.210
|
1.440
|
1.780
|
Cash Flow per Share
2 |
-2.090
|
-2.270
|
-2.370
|
-1.740
|
-0.6200
|
-0.2300
|
0.1200
|
-
|
Capex
1 |
1.97
|
0.18
|
0.67
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
0.84%
|
1.91%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/03/20
|
25/02/21
|
24/02/22
|
30/03/23
|
29/02/24
|
-
|
-
|
-
|
Last Close Price
17.15
USD Average target price
21.67
USD Spread / Average Target +26.34% Consensus |
1st Jan change
|
Capi.
|
---|
| +151.47% | 752M | | +8.96% | 105B | | -1.43% | 104B | | +4.40% | 22.94B | | -12.15% | 22.34B | | -4.36% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +38.61% | 12.63B | | +313.59% | 8.49B |
Bio Therapeutic Drugs
|